Condition: Ovarian Cancer, Epithelial · Gastric Cancer · GastroEsophageal Junction (GEJ) Cancer · Sponsor: Nurix Therapeutics, Inc.
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
This description comes directly from the study's public registry record.
Nurix Therapeutics Patient Outreach · 4152307815 · nx1607101@nurixtx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Completed |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| University of Colorado School of Medicine | Aurora, Colorado, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| University of North Carolina | Chapel Hill, North Carolina, United States | Recruiting |
| University of Oklahoma | Oklahoma City, Oklahoma, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
| Royal Marsden Hospital NHS Foundation Trust | Sutton, Surrey, United Kingdom | Recruiting |
| Addenbrookes Cambridge University Hospital | Cambridge, United Kingdom | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05107674